Hi @Gowtham_Rao, I am very interested in joining this working group. It seems this group is no longer active. Is this topic now under other working groups? Thank you!
No
This workgroup is unfortunately inactive
1 Like
Thank you for your reply!
Hi everyone,
Our team in Pfizer is still quite interested in this working group and we are hoping to see if we can help to re-activate the group. How should we do so?
If anyone was in this working group, do you mind to share what are the challenges you faced, and what’s the key reason that the group is now inactive? I already learned from Rao that the group led to the updated cost table (version 6), and also added features to Atlas for cost and utilization.
Thanks all!
Yi-Chien
Hi everyone,
Our team is also very interested in HEOR research using OMOP-CDM. We’ve conducted three studies on economic analyses and outcomes research using real-world data (RWD), which you can find here:
- [Economic burden of age-related macular degeneration] (JMIR Public Health and Surveillance - Patient-Centered Economic Burden of Exudative Age-Related Macular Degeneration: Retrospective Cohort Study)
- Economic burden and healthcare utilization of diabetic macular edema
- [Bayesian comparative effectiveness research with RCT and RWD] 2024 OHDSI global symposium showcase 77
While I’m not sure why the working group is currently inactive, I would love to participate and contribute to reactivating the HEOR working group. If anyone is interested, we could arrange a personal meeting at the OHDSI 2024 Global Symposium in New Jersey.
Looking forward to working together.
Thanks!
Kyungseon
Did you guys meet? And decide something?
Hi Christian,
Thank you for following up.
- Unfortunately, we haven’t had a chance to meet yet.
- No specific decisions have been made regarding reactivating the HEOR working group.
- I agree that it would be great to discuss this further in the forum and see if there are other interested members.
Looking forward to hearing if anyone else is open to joining the discussion.
Dear OHDSI Community,
I am considering restarting the Workgroup for Cost, Utilization, Economic, and Services, which was initially established to develop methods and software for calculating healthcare resource utilization and costs. This initiative aimed to support descriptive summary statistics for health services research, with a focus on health economics, health insurance, actuarial, and financing use cases.
The workgroup previously discussed concepts such as evaluation and comparator cohorts, index periods, cohort periods, baseline periods, and time series analyses. Preliminary table shells were created to illustrate proposed analysis outputs, including patient demographics, comorbid conditions, medication use, risk scores, and medical service utilization with associated costs.
In October 2024, there was interest expressed in reactivating this workgroup, but no specific decisions were made at that time.
Given the importance of health economics and outcomes research (HEOR) within our community, as highlighted in previous discussions, I believe reactivating this workgroup would be beneficial.
I invite all interested members to share their thoughts on reactivating this workgroup and to indicate their willingness to participate.
Looking forward to your feedback and collaboration.
Best regards,
Gowtham
2 Likes
Hello, I’m a Health Economist and just discovering OHDSI. I would be interesting in collaborating. Best Kati
1 Like
More details to follow, including cadence, mission, etc. The workgroup is being resurrected here Workgroup - Cost and Utilization | General | Microsoft Teams